Trial reportJournal of patient-reported outcomes2026
Validation of PREM-PS, a patient-reported experience instrument, in a randomized controlled trial of pregnant women undergoing prenatal screening.
Trial report in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03831256 (PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood : Towards First Tier Screening and Beyond
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient-reported experience measures are valuable instruments for assessing care quality in alignment with the Triple Aim framework. We sought to validate the PREM-PS questionnaire (Patient Reported Experience Measure – Prenatal Screening) by evaluating its psychometric properties (structural validity, internal consistency, and cross-cultural validity) for Canadian French-and English-speaking populations. METHODOLOGY: This secondary analysis used data from a prospective, open-label, multicenter randomized trial in Quebec and British Columbia (2019–2023). Pregnant women aged 19+ were randomized 2:1 to receive either first-tier cell-free DNA (cfDNA) or traditional biochemical screening for chromosomal anomalies (T21, T18, T13). Participants completed the PREM-PS, a 10-item questionnaire on a 5-point Likert scale, at 22 weeks of pregnancy. Exploratory factor analysis, conducted separately for French and English questionnaires, used half the data to identify underlying factors. Confirmatory factor analysis of the remaining data evaluated structural validity. Internal consistency was assessed using Cronbach’s alpha, and cross-cultural validity through measurement invariance analyses. Mean scores were compared across arms using linear mixed models.
resultsOf 7815 enrolled pregnant women, 3398 completed the French questionnaire and 2875 the English version (80.3% response rate, 96.4% completion rate). Mean age was 32.11 years (SD = 4.01), with 65.1% identifying as White. Factor analyses retained seven items grouped into two latent factors interpreted as Communication and Professionalism. Standardized loadings from exploratory factor analysis ranged from 0.66–0.93 (French) and 0.69–0.96 (English), while standardized parameter estimates from the confirmatory factor analysis ranged from 0.67–0.98 (French) and 0.62–0.98 (English). Cronbach’s alpha exceeded 0.85 for both factors in French and 0.88 in English. No significant differences were observed between the two study arms for either Professionalism or Communication scores, indicating comparable patient-reported experiences regardless of screening method.
conclusionThe PREM-PS demonstrates adequate validity for assessing patient-reported experiences of pregnant women undergoing prenatal screening in both Canadian French and English, with potential to guide improvements in prenatal care.
trial registrationClinicalTrials.gov, NCT03831256. Registered February 5th, 2019, https://clinicaltrials.gov/study/NCT03831256?term=NCT03831256&rank=1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.